Pacific Biosciences of California (PACB)
(Delayed Data from NSDQ)
$1.56 USD
+0.12 (8.33%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $1.55 -0.01 (-0.64%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.56 USD
+0.12 (8.33%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $1.55 -0.01 (-0.64%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum C VGM
Zacks News
Revvity (RVTY) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Revvity's (RVTY) second-quarter results are likely to reflect weak performance at the Diagnostics segment, partially offset by strong demand for Life Sciences and Diagnostics franchise.
McKesson (MCK) to Report Q1 Earnings: Is a Beat in Store?
by Zacks Equity Research
McKesson's (MCK) fiscal first-quarter 2024 results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment.
Pacific Biosciences of California (PACB) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Pacific Biosciences (PACB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is a Beat Likely for AmerisourceBergen (ABC) in Q3 Earnings?
by Zacks Equity Research
AmerisourceBergen's (ABC) fiscal third-quarter 2023 results are likely to reflect solid performance at the U.S. Healthcare Solutions segment.
Stryker (SYK) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Stryker's (SYK) second-quarter 2023 results are expected to reflect strong segmental performance. However, rising costs are likely to have continued hurting margins.
DexCom (DXCM) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
DexCom's (DXCM) second-quarter 2023 results are likely to reflect rising volumes across all channels.
Baxter (BAX) to Post Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Baxter's (BAX) second-quarter results are likely to reflect growth in elective surgical procedures, offset by currency movement. Hillrom's products might have boosted sales.
Intuitive Surgical (ISRG) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
Intuitive Surgical's (ISRG) second-quarter results are likely to reflect solid performance in the Instruments & Accessories segment. However, rising costs may have hurt margins.
3 Reasons to Retain PacBio (PACB) Stock in Your Portfolio
by Zacks Equity Research
PacBio's (PACB) product development activities raise optimism about the stock.
PacBio (PACB) Gets New Order for Revio System From Bioscientia
by Zacks Equity Research
PacBio (PACB) receives new order for its Revio system from Bioscientia that will boost the latter's services. Here's how Revio can help Bioscientia improve diagnosis and treatment for monogenic disorders.
PacBio's (PACB) New Tie-Up to Boost Rare Disease Research
by Zacks Equity Research
PacBio's (PACB) latest collaboration is expected to highlight the feasibility and cost-effectiveness of using its HiFi sequencing technology.
Here's Why You Should Retain PacBio (PACB) Stock for Now
by Zacks Equity Research
PacBio's (PACB) product development activities raise optimism about the stock.
Inari Medical, Inc. (NARI) Down 0.6% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Inari Medical, Inc. (NARI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
PacBio (PACB) Tops on Q1 Earnings, Raises FY23 Revenue View
by Zacks Equity Research
PacBio (PACB) witnesses strong revenue growth in the first quarter. This is partly aided by customers' product transition to the Revio system.
Pacific Biosciences of California (PACB) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Pacific Biosciences (PACB) delivered earnings and revenue surprises of 6.06% and 10.55%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
All You Need to Know About Pacific Biosciences (PACB) Rating Upgrade to Buy
by Zacks Equity Research
Pacific Biosciences (PACB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
PacBio's (PACB) New Offering to Enable High-Throughput Workflows
by Zacks Equity Research
PacBio's (PACB) latest launch is expected to combine the power of HiFi sequencing and Nanobind technology to optimize sample preparation workflows for its high-volume customers.
3 Reasons to Retain PacBio (PACB) Stock in Your Portfolio
by Zacks Equity Research
PacBio's (PACB) product development activities raise optimism about the stock.
Pacific Biosciences (PACB) Stock Jumps 18.7%: Will It Continue to Soar?
by Zacks Equity Research
Pacific Biosciences (PACB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
PacBio (PACB) New Revio Workflows to Boost Agricultural Output
by Zacks Equity Research
PacBio (PACB), in collaboration with Corteva Agriscience, is likely to enable groundbreaking plant and microbial long-read sequencing workflow on Revio system.
Does Pacific Biosciences (PACB) Have the Potential to Rally 30.15% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Pacific Biosciences (PACB) points to a 30.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
PacBio's (PACB) Latest Offering to Enhance Genome Analysis
by Zacks Equity Research
PacBio's (PACB) new informatics analysis method, Paraphase, will enable researchers to genotype gene paralogs and pseudogenes with high accuracy.
PacBio (PACB) Q4 Earnings Match Estimates, Revenues Top
by Zacks Equity Research
Despite robust Consumables revenues, PacBio (PACB) witnesses overall soft performance in the fourth quarter.
Pacific Biosciences of California (PACB) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Pacific Biosciences (PACB) delivered earnings and revenue surprises of 0% and 3.18%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Medical Device Stocks' Q4 Earnings on Feb 16: WST, SWAV & More
by Indrajit Bandyopadhyay
Medical Device players are likely to have benefited from the reopening of economies and several efforts to combat macro headwinds. Let's see how WST, SWAV, AMN, ITGR and PACB are likely to fare this time.